Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epidermolysis bullosa simplex

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Epidermolysis bullosa simplex. Displaying page 1 of 1.
    EudraCT Number: 2017-002332-16 Sponsor Protocol Number: RC31-16-8917 Start Date*: 2017-10-03
    Sponsor Name:Toulouse Hospital
    Full Title: Evaluation of the efficacy of injections of botulinic toxin in plantar lesions of patients suffering from localized epidermolysis bullosa simplex : double blind randomized controlled study.
    Medical condition: localized epidermolysis bullosa simplex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005679-96 Sponsor Protocol Number: SD-006 Start Date*: 2015-03-16
    Sponsor Name:Scioderm, INC
    Full Title: An Open Label, Multi-center, Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients with Epidermolysis Bullosa
    Medical condition: Epidermolysis Bullosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) NL (Completed) GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002288-14 Sponsor Protocol Number: SD-005 Start Date*: 2014-08-08
    Sponsor Name:Scioderm, An Amicus Therapeutics Company
    Full Title: A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa
    Medical condition: Epidermolysis Bullosa
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) GB (Completed) IT (Completed) DE (Completed) PL (Completed) ES (Completed) LT (Completed) BE (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-003757-41 Sponsor Protocol Number: CCP-020-302 Start Date*: 2018-02-19
    Sponsor Name:Castle Creek Pharmaceuticals, LLC
    Full Title: An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)
    Medical condition: Epidermolysis Bullosa Simplex (EBS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) NL (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004427-24 Sponsor Protocol Number: CCP-020-301 Start Date*: 2017-08-24
    Sponsor Name:Castle Creek Pharmaceuticals, LLC
    Full Title: An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis ...
    Medical condition: Epidermolysis Bullosa Simplex (EBS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000214-42 Sponsor Protocol Number: 755-201-EB Start Date*: Information not available in EudraCT
    Sponsor Name:InMed Pharmaceuticals Inc.
    Full Title: A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabinol) Cream in Patients with Epidermolysis Bullosa.
    Medical condition: Epidermolysis bullosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) GR (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-002034-21 Sponsor Protocol Number: Dia2014 Start Date*: 2013-12-16
    Sponsor Name:EB House Austria
    Full Title: Diacerein for the treatment of Epidermolysis bullosa simplex
    Medical condition: Epidermolysis bullosa simplex - type Dowling-Meara
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001542-19 Sponsor Protocol Number: 20-PP-04 Start Date*: 2020-07-22
    Sponsor Name:CHU NICE
    Full Title: A 12-Week Multicentre, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Placebo in Patients > 6 years of age with EB simplex generalized severe
    Medical condition: Epidermolysis bullosa simplex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010763-17 Sponsor Protocol Number: EBSBTXA09 Start Date*: 2009-05-26
    Sponsor Name:Sophiahemmet
    Full Title: Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia congenita-a double-blind placebo-controlled phase II proof of concept study
    Medical condition: Epidermolysis Bullosa Simplex and Pachyonychia Congenita
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000103-20 Sponsor Protocol Number: 202000638 Start Date*: 2021-07-15
    Sponsor Name:University Medical Center Groningen
    Full Title: An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa
    Medical condition: Genetic Epidermolysis Bullosa
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:32:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA